10
Participants
Start Date
April 30, 2007
Primary Completion Date
August 25, 2010
Study Completion Date
August 27, 2010
Dasatinib
Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
Weill Cornell Medical College - New York Presbyterian Hospital, New York
Hematology/Oncology Associates of Rockland, New City
Emory Winship Cancer Institute, Atlanta
The Jones Clinic, Germantown
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Weill Medical College of Cornell University
OTHER